CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating BRAF mutations are common in melanoma, leading to initial responses to BRAF inhibitors.
• Acquired drug resistance limits the long-term efficacy of BRAF inhibitors in melanoma patients.
• Understanding resistance mechanisms is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To identify novel therapeutic targets for BRAF inhibitor-resistant melanoma.
• To investigate the molecular mechanisms and pathways driving resistance to BRAF inhibitors.
• To elucidate gene regulatory networks in melanoma cells that confer resistance.

Main Methods:

• CRISPR screens were performed on melanoma cells with BRAF mutations and acquired resistance to BRAF inhibitors.
• Integration of transcriptomic, ATAC-seq, and CRISPR screen data was used to identify key regulators.
• Functional validation of identified genes in melanoma models.

Main Results:

• JUN family transcription factors and ETV5 were identified as key regulators of CDK6.
• These factors were found to enable resistance to BRAF inhibitors in melanoma cells.
• Specific genes contributing to resistance against the BRAF inhibitor PLX4720 were revealed.

Conclusions:

• JUN and ETV5, through regulation of CDK6, play a critical role in BRAF inhibitor resistance in melanoma.
• These findings provide new insights into gene regulation underlying melanoma drug resistance.
• Targeting JUN, ETV5, or CDK6 may represent a viable therapeutic strategy for resistant melanoma.